GSK Investigational Site

Nottingham, Nottinghamshire NG7 2UH

0 studies enrolling now · 7 studies all time

What they study most

Acute Coronary Syndrome, Diabetes Mellitus, Type 2, Hepatitis C, Hepatitis C, Chronic, Neoplasms, Neoplasms, Prostate, Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer, Thrombocytopenia

Studies at this site

• Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer — Stopped early
• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer — Completed
• Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide — Completed
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• ARI103094-Follow-Up Study for REDUCE Study Subjects — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C — Completed